» Articles » PMID: 16115224

Metastatic Neoplasms Involving the Ovary: a Review with an Emphasis on Morphological and Immunohistochemical Features

Overview
Journal Histopathology
Date 2005 Aug 24
PMID 16115224
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

The ovary is a common site of metastatic tumour. In many cases of ovarian metastasis there is a known history of malignancy but in other cases the ovarian tumour is the first manifestation of disease. In this review metastatic colorectal, appendiceal, gastric, breast, pancreatic and biliary tract, hepatocellular, renal, transitional and cervical carcinomas and metastatic malignant melanoma involving the ovary are discussed, as is the issue of synchronous ovarian and endometrial carcinomas. Peritoneal tumours, including primary peritoneal carcinoma, mesothelioma and intra-abdominal desmoplastic small round cell tumour, involving the ovary are also discussed, together with a variety of other rare, metastatic ovarian neoplasms. Many metastatic adenocarcinomas involving the ovary, especially those exhibiting mucinous differentiation, closely mimic primary ovarian adenocarcinomas with morphologically bland areas simulating benign and borderline cystadenoma. This is referred to as a maturation phenomenon. In recent years immunohistochemistry, especially but not exclusively differential cytokeratin (CK7 and CK20) staining, has been widely used as an aid to distinguish between a primary and secondary ovarian adenocarcinoma. While immunohistochemistry undoubtedly has a valuable role to play and is paramount in diagnosis in some cases, the results must be interepreted with caution, especially in mucinous tumours, and within the relevant clinical context. We feel the significance of differential cytokeratin staining is not always understood by histopathologists and this can result in erroneous interpretation. We critically discuss the value of immunohistochemistry and associated pitfalls with each tumour type described.

Citing Articles

Utilization of immunohistochemistry in gynecologic tumors: An expert review.

Katcher A, Greenman M, Roychoudhury S, Goldberg G Gynecol Oncol Rep. 2024; 56:101550.

PMID: 39717157 PMC: 11664289. DOI: 10.1016/j.gore.2024.101550.


Status of and Challenges in Therapy of Mucinous Ovarian Cancer Associated with Pseudomyxoma Peritonei Syndrome: Review of Current Options and Future Treatment Trends.

Pariza G, Mavrodin C, Potorac A, Munteanu O, Cirstoiu M Life (Basel). 2024; 14(11).

PMID: 39598188 PMC: 11595252. DOI: 10.3390/life14111390.


Multiparametric MRI-based radiomics nomogram for differentiation of primary mucinous ovarian cancer from metastatic ovarian cancer.

Shi S, Li Y, Qiang J Abdom Radiol (NY). 2024; 50(2):1018-1028.

PMID: 39215773 DOI: 10.1007/s00261-024-04542-y.


Molecular image-guided surgery in gynaecological cancer: where do we stand?.

Pisano G, Wendler T, Olmos R, Garganese G, Rietbergen D, Giammarile F Eur J Nucl Med Mol Imaging. 2024; 51(10):3026-3039.

PMID: 38233609 PMC: 11300493. DOI: 10.1007/s00259-024-06604-1.


The clinicopathological characteristics and survival outcomes of primary expansile infiltrative mucinous ovarian adenocarcinoma: a retrospective study sharing the experience of a tertiary centre.

Nistor S, El-Tawab S, Wong F, Zouridis A, Roux R, Manek S Transl Cancer Res. 2023; 12(10):2682-2692.

PMID: 37969399 PMC: 10643958. DOI: 10.21037/tcr-23-863.